GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (XSWX:MOR) » Definitions » Short Ratio

MorphoSys AG (XSWX:MOR) Short Ratio


View and export this data going back to 1999. Start your Free Trial

What is MorphoSys AG Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


MorphoSys AG (XSWX:MOR) Business Description

Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

MorphoSys AG (XSWX:MOR) Headlines

From GuruFocus

MorphoSys AG Reports First Quarter 2023 Financial Results

By Business Wire Business Wire 05-03-2023

MorphoSys AG: Financial Calendar 2023

By ACCESSWIRE ACCESSWIRE 11-29-2022